Day 1, week 1 and week 12 data from patient daily diaries
| Diary PRO measures | Day 1 Median (IQR) | Week 1 Median (IQR) | Week 12 Median (IQR) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Placebo (N=228) | Baricitinib 2 mg (N=229) | Baricitinib 4 mg (N=227) | Placebo (N=228) | Baricitinib 2 mg (N=229) | Baricitinib 4 mg (N=227) | Placebo (N=228) | Baricitinib 2 mg (N=229) | Baricitinib 4 mg (N=227) | |
| Duration of morning joint stiffness, min | 60.0 (30.0, 180.0) | 80.0 (30.0, 180.0) | 75.0 (30.0, 180.0) | 84.0 (36.8, 195.0) | 80.0 (36.7, 157.5) | 80.0 (32.9, 188.6) | 60.0 (22.9, 162.9) | 44.4** (9.1, 120.0) | 34.6*** (7.4, 96.4) |
|
Day 1 Mean (SD) | Week 1 LSM (95% CI) | Week 12 LSM (95% CI) | |||||||
| Severity of morning joint stiffness | 5.5 (2.1) | 5.5 (2.1) | 5.3 (2.1) | 5.1 (5.0 to 5.3) | 5.0 (4.8 to 5.2) | 4.9* (4.7 to 5.1) | 4.1 (3.8 to 4.4) | 3.5** (3.2 to 3.8) | 3.4*** (3.1 to 3.7) |
| Worst Tiredness | 5.8 (2.0) | 5.7 (2.3) | 5.7 (2.2) | 5.2 (5.0 to 5.4) | 5.2 (5.0 to 5.4) | 5.0 (4.9 to 5.2) | 4.5 (4.2 to 4.8) | 4.1* (3.8 to 4.4) | 4.0* (3.7 to 4.4) |
| Worst Joint Pain | 5.8 (2.0) | 5.9 (2.2) | 5.7 (2.0) | 5.6 (5.4 to 5.8) | 5.3 (5.2 to 5.5) | 5.2** (5.0 to 5.4) | 4.7 (4.4 to 5.0) | 3.8*** (3.5 to 4.1) | 3.8*** (3.5 to 4.2) |
*p≤0.05; **p≤0.01; ***p≤0.001.
LSM, least-squares mean.